98%
921
2 minutes
20
The external part of the eye shares mucosa-associated common characteristics and is an obvious entry site for foreign Ags. We assessed the potential of eyedrop vaccination for effective delivery of vaccines against viral or bacterial infection in mice. Both OVA-specific IgG Ab in serum and IgA Ab in mucosal compartments were induced by eyedrops of OVA with cholera toxin (CT). Eyedrop vaccination of influenza A/PR/8 virus (H1N1) induced both influenza virus-specific systemic and mucosal Ab responses and protected mice completely against respiratory infection with influenza A/PR/8 virus. In addition, eyedrop vaccination of attenuated Salmonella vaccine strains induced LPS-specific Ab and complete protection against oral challenge of virulent Salmonella. Unlike with the intranasal route, eyedrop vaccinations did not redirect administered Ag into the CNS in the presence of CT. When mice were vaccinated by eyedrop, even after the occlusion of tear drainage from eye to nose, Ag-specific systemic IgG and mucosal IgA Abs could be induced effectively. Of note, eyedrops with OVA plus CT induced organogenesis of conjunctiva-associated lymphoid tissue and increased microfold cell-like cells on the conjunctiva-associated lymphoid tissue in the nictitating membrane on conjunctiva, the mucosal side of the external eye. On the basis of these findings, we propose that the eyedrop route is an alternative to mucosal routes for administering vaccines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4049/jimmunol.1000680 | DOI Listing |
J Vet Med Sci
July 2025
Vaxxinova Japan K.K., Tochigi, Japan.
A field isolate of Mycoplasma synoviae, designated D14-383, caused pathogenic lesions in the air sac, trachea, lung, and ovary and induced a decline or stop in egg production and eggshell apex abnormalities in chickens after intratracheal inoculation. A live M. synoviae vaccine candidate was developed after in vitro passaging at 32°C from a wild-type M.
View Article and Find Full Text PDFInt J Biol Macromol
May 2025
Centre for Drug Delivery Technology & Vaccine, Faculty of Pharmacy, University Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia.
Pullulan, an exopolysaccharide, obtained from the fungus Aureobasidium pullulans, is a non-ionic, hydrophilic, biodegradable, biocompatible, and tolerogenic polymers that is used for the formulation of bioconjugates in the therapeutic delivery to target different cells and tissues. It is known to possess outstanding film-casting qualities and can produce a clear and biodegradable film. Furthermore, appropriate derivatizing pullulan provides active surfaces that facilitate binding with active pharmaceutical ingredients to the polymer backbone to produce micro/nanoparticulate systems for controlled or sustained drug release.
View Article and Find Full Text PDFVaccines (Basel)
November 2024
Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China.
Pigeon paramyxovirus type 1 (PPMV-1) is a significant pathogen affecting pigeon populations globally. The commonly used La Sota vaccine provides limited protection due to antigenic divergence from circulating PPMV-1 strains. An antigenically matched vaccine is needed to address this challenge.
View Article and Find Full Text PDFViruses
June 2024
Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.
Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are widespread human pathogens that establish chronic latent infections leading to recurrent episodes. Current treatments are limited, necessitating the development of novel antiviral strategies. This study aimed to assess the antiviral efficacy of novel topical formulations containing interferon alpha-2b (IFN α-2b) against HSV-1 and HSV-2.
View Article and Find Full Text PDF